PCYT2 activity has been shown to be increased in breast cancer cells, enabling them to adapt to metabolic stress [45], and TRERF1 acts as a cell cycle inhibitor in breast cancer cells through the modulation of progesterone receptor [46]. The gene discussed is PCYT2; the disease is breast cancer.